Bruner Katherine M, Murray Alexandra J, Pollack Ross A, Soliman Mary G, Laskey Sarah B, Capoferri Adam A, Lai Jun, Strain Matthew C, Lada Steven M, Hoh Rebecca, Ho Ya-Chi, Richman Douglas D, Deeks Steven G, Siliciano Janet D, Siliciano Robert F
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Howard Hughes Medical Institute, Baltimore, Maryland, USA.
Nat Med. 2016 Sep;22(9):1043-9. doi: 10.1038/nm.4156. Epub 2016 Aug 8.
Although antiretroviral therapy (ART) suppresses viral replication to clinically undetectable levels, human immunodeficiency virus type 1 (HIV-1) persists in CD4(+) T cells in a latent form that is not targeted by the immune system or by ART. This latent reservoir is a major barrier to curing individuals of HIV-1 infection. Many individuals initiate ART during chronic infection, and in this setting, most proviruses are defective. However, the dynamics of the accumulation and the persistence of defective proviruses during acute HIV-1 infection are largely unknown. Here we show that defective proviruses accumulate rapidly within the first few weeks of infection to make up over 93% of all proviruses, regardless of how early ART is initiated. By using an unbiased method to amplify near-full-length proviral genomes from HIV-1-infected adults treated at different stages of infection, we demonstrate that early initiation of ART limits the size of the reservoir but does not profoundly affect the proviral landscape. This analysis allows us to revise our understanding of the composition of proviral populations and estimate the true reservoir size in individuals who were treated early versus late in infection. Additionally, we demonstrate that common assays for measuring the reservoir do not correlate with reservoir size, as determined by the number of genetically intact proviruses. These findings reveal hurdles that must be overcome to successfully analyze future HIV-1 cure strategies.
尽管抗逆转录病毒疗法(ART)可将病毒复制抑制到临床检测不到的水平,但1型人类免疫缺陷病毒(HIV-1)仍以潜伏形式存在于CD4(+) T细胞中,免疫系统或ART都无法靶向这种潜伏形式。这种潜伏库是治愈HIV-1感染者的主要障碍。许多个体在慢性感染期间开始接受ART治疗,在这种情况下,大多数前病毒都是有缺陷的。然而,在急性HIV-1感染期间有缺陷前病毒的积累和持续存在的动态情况在很大程度上尚不清楚。在这里,我们表明,无论ART启动得多早,有缺陷的前病毒在感染后的头几周内迅速积累,占所有前病毒的93%以上。通过使用一种无偏倚的方法从处于不同感染阶段接受治疗的HIV-1感染成人中扩增近全长前病毒基因组,我们证明早期启动ART会限制潜伏库的大小,但不会对前病毒格局产生深远影响。这项分析使我们能够修正我们对前病毒群体组成的理解,并估计在感染早期和晚期接受治疗的个体中的真正潜伏库大小。此外,我们证明,用于测量潜伏库的常用检测方法与潜伏库大小不相关,潜伏库大小是由基因完整的前病毒数量决定的。这些发现揭示了成功分析未来HIV-1治愈策略必须克服的障碍。